Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cytokinetics Inc shares valued at $1,183,391 were sold by Blum Robert I on Jun 17 ’24. At $52.60 per share, Blum Robert I sold 22,500 shares. The insider’s holdings dropped to 416,645 shares worth approximately $21.64 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, PARSHALL B LYNNE sold 5,000 shares, netting a total of over 262,750 in proceeds. Following the sale of shares at $52.55 each, the insider now holds 20,600 shares.
Before that, Malik Fady Ibraham had sold 7,788 shares from its account. In a trade valued at $413,106, the EVP Research & Development traded Cytokinetics Inc shares for $53.04 each. Upon closing the transaction, the insider’s holdings decreased to 7,788 shares, worth approximately $7.01 million.
As published in a research note from UBS on January 24, 2024, Cytokinetics Inc [CYTK] has been rated down from a Buy to a Neutral and the price target has been revised to $92 from $61. Analysts at Morgan Stanley downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal-weight”‘ outlook in a report released in early January. As of November 09, 2023, Goldman has initiated its “Buy” rating for CYTK. Earlier on November 07, 2023, B. Riley Securities initiated its rating. Their recommendation was “a Buy” for CYTK stock.
Analyzing CYTK Stock Performance
During the last five days, there has been a drop of approximately -2.53%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -37.79%. Shares of the company reached a 52-week high of $110.25 on 01/08/24 and a 52-week low of $46.25 on 05/28/24. A 50-day SMA is recorded $60.00, while a 200-day SMA reached $55.47. Nevertheless, trading volume fell to 1.04 million shares from 1.42 million shares the previous day.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 51.19, which, if violated, would cause prices to drop to 50.45. In the upper region, resistance lies at 53.06. The next price resistance is at 54.19. RSI (Relative Strength Index) is 42.25 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.85, which suggests the price will decrease in the coming days. Percent R is at 38.35%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
